Iconovo has signed a Letter of Understanding with CrystecPharma to collaborate on the design and development of new dry powder inhaler (DPI) products to be used for precise drug delivery into the lungs of patients with a wide variety of lung diseases, including pulmonary hypertension. Many…
News
Fifteen out of 18 patients (83%) enrolled in the Phase 2 HELP study testing levosimendan achieved the predefined response required in the open-label phase of the study, Tenax Therapeutics announced. The investigational therapy is a potential treatment for pulmonary hypertension (PH) and heart failure with preserved ejection fraction (PH-HFpEF). The response…
November is Pulmonary Hypertension Awareness Month, and this year, the Pulmonary Hypertension Association (PHA) is highlighting risk factors and symptoms associated with the disease. PHA’s social media campaign, titled “PHaces of Hope,” is based on stories from pulmonary hypertension (PH) patients and their caregivers, as well…
Having pulmonary hypertension (PH) does not affect the benefits of lung volume reduction surgery for people with emphysema, who experience improved lung function and better quality of life, a new study suggests. The study, published in The Annals of Thoracic Surgery, was titled “Pulmonary Hypertension: A…
INOpulse can improve physical activity in people with pulmonary hypertension associated with interstitial lung disease (PH-ILD) and helps them to maintain a higher level of activity, data presented at the 2019 meeting of the American College of Chest Physicians suggest. INOpulse is a therapy that uses inhaled nitric oxide (iNO),…
Oral treatment with rodatristat ethyl is safe and reduced the levels of serotonin — a hormone whose high levels may promote the tightening of pulmonary artery muscle cells — in healthy volunteers, a study has shown. The results were presented in a poster, titled “Once Daily Oral Dosing…
A combination of Opsumit (macitentan) plus Adcirca (tadalafil) lowered pulmonary vascular resistance — a measure showing how well blood flows through vessels — by 47% in people newly diagnosed with pulmonary arterial hypertension (PAH) and improved their physical capacity, new data show. Olivier Sitbon, MD, PhD, with Université Paris–Sud presented the…
Higher levels of a protein involved in certain immune responses, called soluble suppression of tumorigenicity-2 (sST2), are associated with more severe pulmonary hypertension (PH) and heart dysfunction, a study found. This protein’s potential use as a prognostic biomarker for PH, however, seems to be limited. The study, “The Prognostic Value of…
Adcirca (tadalafil) helped to improve survival in dogs with pulmonary hypertension (PH), a new study suggests. Knowing the underlying conditions associated with PH can lead to improved health outcomes in dogs, the study stated. The findings might also prove to be important in understanding the disease in humans.
Treatment with Adcirca (tadalafil) plus Opsumit (macitentan) can provide functional benefits and lessen symptoms in newly diagnosed patients with pulmonary arterial hypertension (PAH), results from a clinical trial show. The data will be discussed at the upcoming CHEST Annual Meeting 2019, to be held Oct. 19-23…
To help those with heart and circulatory disorders live longer and better lives, the British Heart Foundation (BHF) has awarded the University College London (UCL) a £1 million grant (about $1.28 million) over five years. Specifically, funding from the BHF Research Accelerator Award will help UCL build a…
The mechanics of pulmonary hypertension (PH) create a cascade of events that affect the cardiovascular system, kidneys, respiratory system, and digestive system. Though symptoms, which persist over time, primarily lead to changes in breathing…
